OCP

Zineh recently answered PGx Reporter's questions about the agency's efforts in pharmacogenomics and personalized medicine.

NHLBI plans to launch next month the prospectively designed, randomized-controlled study, called Clarification of Optimal Anticoagulation through Genetics trial, which will follow 1,200 patients to see if PGx-guided dosing is clinically useful.